IN2015DN01857A - - Google Patents

Info

Publication number
IN2015DN01857A
IN2015DN01857A IN1857DEN2015A IN2015DN01857A IN 2015DN01857 A IN2015DN01857 A IN 2015DN01857A IN 1857DEN2015 A IN1857DEN2015 A IN 1857DEN2015A IN 2015DN01857 A IN2015DN01857 A IN 2015DN01857A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of IN2015DN01857A publication Critical patent/IN2015DN01857A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1857DEN2015 2012-08-29 2015-03-05 IN2015DN01857A (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694672P 2012-08-29 2012-08-29
US201261723027P 2012-11-06 2012-11-06
PCT/AU2013/000973 WO2014032108A1 (en) 2012-08-29 2013-08-29 Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions

Publications (1)

Publication Number Publication Date
IN2015DN01857A true IN2015DN01857A (https=) 2015-05-29

Family

ID=50182266

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1857DEN2015 IN2015DN01857A (https=) 2012-08-29 2015-03-05

Country Status (15)

Country Link
US (1) US20150216806A1 (https=)
EP (1) EP2890367A4 (https=)
JP (1) JP2015531770A (https=)
KR (1) KR20150046310A (https=)
CN (1) CN104936581A (https=)
AU (1) AU2013308403B2 (https=)
BR (1) BR112015004165A2 (https=)
CA (1) CA2882316A1 (https=)
HK (1) HK1212222A1 (https=)
IL (1) IL237276A0 (https=)
IN (1) IN2015DN01857A (https=)
MX (1) MX2015002210A (https=)
PH (1) PH12015500435A1 (https=)
RU (1) RU2015111258A (https=)
WO (1) WO2014032108A1 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
HUE046754T2 (hu) 2013-03-15 2020-03-30 Braintree Laboratories Inc Kettõs felhasználású orális gyógyszer kompozíció tabletták szulfát sókból és eljárás ezek alkalmazására
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US20160089363A1 (en) * 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
US10105360B2 (en) * 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
WO2015086528A1 (de) 2013-12-11 2015-06-18 Develco Pharma Schweiz Ag Naloxon-monopräparat und mehrschichttablette
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
RO130546B1 (ro) * 2014-04-28 2019-03-29 Mariana Lisinschi Unguent pentru tratamentul bolii hemoroidale
CA2947434A1 (en) 2014-04-29 2015-11-05 Colonaryconcepts Llc Foods, systems, methods, and kits for providing electrolyte replacement
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016140981A1 (en) 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN107750124B (zh) * 2015-05-06 2022-10-28 波利维逊有限公司 用于降低微生物污染的抗微生物组合物和方法
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
CA2995798A1 (en) 2015-08-17 2017-02-23 Nipul Ghanshyambhai PATEL Liquid formulations containing picosulfate and magnesium citrate
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP2019507121A (ja) * 2016-01-28 2019-03-14 シーティーシー バイオ,インコーポレイテッド 下剤組成物
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
AU2017241904A1 (en) * 2016-03-29 2018-10-18 Colonaryconcepts Llc Formulations for treating constipation
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TW201804996A (zh) 2016-07-08 2018-02-16 輝凌責任有限公司 含有匹可硫酸鹽(picosulfate)之安定液體調配物
US20190298735A1 (en) * 2016-07-08 2019-10-03 Vanderbilt University Treatment and prevention of clostridium difficile colitis using misoprostol
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
CN106556666A (zh) * 2016-11-02 2017-04-05 陕西嘉禾生物科技股份有限公司 一种欧鼠李皮和美鼠李皮的薄层鉴定方法
IT201600122310A1 (it) * 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN106830417B (zh) * 2017-01-12 2021-05-11 新宇药业股份有限公司 一种高效降解废水中林可霉素的处理方法
CN107616984A (zh) * 2017-01-13 2018-01-23 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
CN107616983A (zh) * 2017-01-13 2018-01-23 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
CN107518411A (zh) * 2017-01-13 2017-12-29 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
EP3737245A4 (en) * 2018-01-12 2021-08-25 Colonaryconcepts LLC CONCENTRATED SOLID FORMULATIONS FOR CONSTIPATION TREATMENT
WO2019140319A1 (en) * 2018-01-12 2019-07-18 Colonaryconcepts Llc Constipation specific treatment formulations
IL277332B2 (en) * 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation
CN110403945B (zh) * 2018-04-28 2022-11-18 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物及其制备方法
CN115581699A (zh) * 2018-04-28 2023-01-10 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物及其制备方法
CN108819052A (zh) * 2018-05-04 2018-11-16 苏州捷德瑞精密机械有限公司 一种树脂基体系用脱模剂及其制备方法
AU2019278927A1 (en) * 2018-06-01 2020-12-24 Bt Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
JP6661712B2 (ja) * 2018-08-15 2020-03-11 旭化成ワッカーシリコーン株式会社 シリコーン消泡剤組成物、および、シリコーン消泡剤組成物の製造方法。
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物
CN109337098B (zh) * 2018-11-23 2021-02-02 哈尔滨工程大学 一种酶响应型结肠靶向载药凝胶的制备方法
CN109749960B (zh) * 2019-01-31 2020-05-26 上海宝藤生物医药科技股份有限公司 基于多种肠道细菌含量评估便秘风险及便秘程度的方法及装置
US10857092B2 (en) * 2019-03-14 2020-12-08 Glen D Lindbo Avoiding gag reflex to enable swallowing pills
WO2020191076A1 (en) * 2019-03-18 2020-09-24 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
CN110051655A (zh) * 2019-03-19 2019-07-26 吉林省盛赛医药实业有限公司 一种治疗便秘的复方制剂的制备方法
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
WO2021007318A1 (en) * 2019-07-08 2021-01-14 Arjil Biotech Holding Company Limited Composition and method for treating gastrointestinal disorder
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
CN112386577B (zh) * 2019-08-16 2024-01-23 北京天衡药物研究院有限公司 一种治疗便秘的组合物
RU2716144C1 (ru) * 2019-09-23 2020-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ консервативного лечения послеоперационного пареза кишечника у новорожденных детей
CN110833537B (zh) * 2019-11-15 2021-04-13 三峡大学 药物缓释材料及其在制备治疗直肠炎的缓释材料上的应用
CN111920798A (zh) * 2020-06-24 2020-11-13 首都医科大学附属北京同仁医院 一种硝呋酚酰肼在制备药物中的应用
CN112843077A (zh) * 2020-09-08 2021-05-28 天津国际生物医药联合研究院 表柔比星或者硫酸博来霉素在抗分枝杆菌感染中的潜在应用
CN112189761A (zh) * 2020-10-30 2021-01-08 安佑生物科技集团股份有限公司 一种防治动物便秘的饲料添加剂及其制备方法和应用
CN114869879B (zh) * 2022-05-09 2024-06-25 南方医科大学珠江医院 一种具备活性氧和炎症双重抑制作用的小分子水凝胶及其制备方法
CN114965764B (zh) * 2022-05-18 2024-12-31 陕西安宁云生生物技术有限公司 便秘的诊断和治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA761927A (en) * 1967-06-27 Seeger Ernst Benzoxazine derivatives
JP5068401B2 (ja) * 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Hpmcカプセルを使用する腸及び結腸への送達
CN1288730A (zh) * 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
CA2514879C (en) * 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
CN103338768B (zh) * 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法

Also Published As

Publication number Publication date
JP2015531770A (ja) 2015-11-05
RU2015111258A (ru) 2016-10-20
EP2890367A1 (en) 2015-07-08
HK1212222A1 (en) 2016-06-10
CN104936581A (zh) 2015-09-23
AU2013308403A1 (en) 2015-03-05
PH12015500435A1 (en) 2015-04-20
KR20150046310A (ko) 2015-04-29
CA2882316A1 (en) 2014-03-06
EP2890367A4 (en) 2016-03-30
AU2013308403B2 (en) 2019-02-07
WO2014032108A1 (en) 2014-03-06
IL237276A0 (en) 2015-04-30
BR112015004165A2 (pt) 2017-07-04
MX2015002210A (es) 2015-05-08
US20150216806A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
IN2015DN01857A (https=)
BR122019026149A2 (https=)
BR112014017635A2 (https=)
BR112014017614A2 (https=)
BR112014017625A2 (https=)
BR112014017659A2 (https=)
BR112014017607A2 (https=)
BR112014017646A2 (https=)
BR112014017638A2 (https=)
BR112014017609A2 (https=)
BR112014017644A2 (https=)
BR112014017634A2 (https=)
BR112014017647A2 (https=)
BR112014017618A2 (https=)
BR112014017627A2 (https=)
BR112014017623A2 (https=)
BR112014017652A2 (https=)
BR112014020806A2 (https=)
BR112014017630A2 (https=)
BR112014018299A2 (https=)
BR112014019303A2 (https=)
BR112014017621A2 (https=)
BR112014017631A2 (https=)
BR112014017641A2 (https=)
BR112014017622A2 (https=)